137 related articles for article (PubMed ID: 20848733)
1. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis.
Faller WJ; Rafferty M; Hegarty S; Gremel G; Ryan D; Fraga MF; Esteller M; Dervan PA; Gallagher WM
Melanoma Res; 2010 Oct; 20(5):392-400. PubMed ID: 20848733
[TBL] [Abstract][Full Text] [Related]
2. Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin.
Li N; Liu Y; Pang H; Lee D; Zhou Y; Xiao Z
Med Sci Monit; 2019 Mar; 25():1590-1599. PubMed ID: 30821276
[TBL] [Abstract][Full Text] [Related]
3. Identification of MT1E as a novel tumor suppressor in hepatocellular carcinoma.
Liu Q; Lu F; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153213. PubMed ID: 32956919
[TBL] [Abstract][Full Text] [Related]
4. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
[TBL] [Abstract][Full Text] [Related]
5. Silencing of metallothionein 1A gene in melanoma.
Nobeyama Y; Nakagawa H
J Dermatol Sci; 2017 Nov; 88(2):232-237. PubMed ID: 28764861
[TBL] [Abstract][Full Text] [Related]
6. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies.
Gallagher WM; Bergin OE; Rafferty M; Kelly ZD; Nolan IM; Fox EJ; Culhane AC; McArdle L; Fraga MF; Hughes L; Currid CA; O'Mahony F; Byrne A; Murphy AA; Moss C; McDonnell S; Stallings RL; Plumb JA; Esteller M; Brown R; Dervan PA; Easty DJ
Carcinogenesis; 2005 Nov; 26(11):1856-67. PubMed ID: 15958521
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma.
Maleckaite R; Zalimas A; Bakavicius A; Jankevicius F; Jarmalaite S; Daniunaite K
Oncol Rep; 2019 Jun; 41(6):3535-3544. PubMed ID: 31002354
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
9. Role of metallothionein 1E in the migration and invasion of human glioma cell lines.
Ryu HH; Jung S; Jung TY; Moon KS; Kim IY; Jeong YI; Jin SG; Pei J; Wen M; Jang WY
Int J Oncol; 2012 Oct; 41(4):1305-13. PubMed ID: 22843066
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Chen YP; Hou XY; Yang CS; Jiang XX; Yang M; Xu XF; Feng SX; Liu YQ; Jiang G
Tumour Biol; 2016 Aug; 37(8):11209-18. PubMed ID: 26943799
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Marini A; Mirmohammadsadegh A; Nambiar S; Gustrau A; Ruzicka T; Hengge UR
J Invest Dermatol; 2006 Feb; 126(2):422-31. PubMed ID: 16374457
[TBL] [Abstract][Full Text] [Related]
13. Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.
Mithani SK; Smith IM; Califano JA
Melanoma Res; 2011 Aug; 21(4):298-307. PubMed ID: 21606880
[TBL] [Abstract][Full Text] [Related]
14. Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin.
Guo J; Zhang J; Liang L; Liu N; Qi M; Zhao S; Su J; Liu J; Peng C; Chen X; Liu H
J Cell Mol Med; 2020 Apr; 24(7):4324-4340. PubMed ID: 32129945
[TBL] [Abstract][Full Text] [Related]
15. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma.
Guan X; Sagara J; Yokoyama T; Koganehira Y; Oguchi M; Saida T; Taniguchi S
Int J Cancer; 2003 Nov; 107(2):202-8. PubMed ID: 12949795
[TBL] [Abstract][Full Text] [Related]
16. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
18. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
19. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Bae SI; Cheriyath V; Jacobs BS; Reu FJ; Borden EC
Oncogene; 2008 Jan; 27(4):490-8. PubMed ID: 17653094
[TBL] [Abstract][Full Text] [Related]
20. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
